Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

Similar articles for PubMed (Select 22280104)

1.

Glomulin: a permissivity factor for vaccinia virus infection.

Rahbar R, Rogers E, Murooka T, Kislinger T, Fish EN.

J Interferon Cytokine Res. 2012 Mar;32(3):127-37. doi: 10.1089/jir.2011.0100. Epub 2012 Jan 26.

PMID:
22280104
2.

Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication.

Rahbar R, Murooka TT, Hinek AA, Galligan CL, Sassano A, Yu C, Srivastava K, Platanias LC, Fish EN.

J Virol. 2006 Jul;80(14):7245-59.

3.

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R.

Cancer Res. 2003 Sep 1;63(17):5462-9.

4.

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R.

Cancer Res. 2005 Feb 15;65(4):1479-88.

5.

Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha.

Backes S, Sperling KM, Zwilling J, Gasteiger G, Ludwig H, Kremmer E, Schwantes A, Staib C, Sutter G.

J Gen Virol. 2010 Feb;91(Pt 2):470-82. doi: 10.1099/vir.0.015347-0. Epub 2009 Oct 21.

PMID:
19846675
6.

The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Tulasne D, Paumelle R, Weidner KM, Vandenbunder B, Fafeur V.

Mol Biol Cell. 1999 Mar;10(3):551-65.

7.

Role for CCR5 in dissemination of vaccinia virus in vivo.

Rahbar R, Murooka TT, Fish EN.

J Virol. 2009 Mar;83(5):2226-36. doi: 10.1128/JVI.01655-08. Epub 2008 Dec 10.

8.

Non-T cell activation linker regulates ERK activation in Helicobacter pylori-infected epithelial cells.

Rieke C, Kähne T, Schweitzer K, Schraven B, Wienands J, Engelke M, Naumann M.

Cell Signal. 2010 Mar;22(3):395-403. doi: 10.1016/j.cellsig.2009.10.010. Epub .

PMID:
19879355
9.

Fas-signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells.

Shen K, Novak RF.

Biochem Biophys Res Commun. 1997 Jan 3;230(1):89-93.

PMID:
9020068
10.
11.
12.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.

Clin Cancer Res. 2004 Oct 1;10(19):6686-94.

13.

Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication.

Soares JA, Leite FG, Andrade LG, Torres AA, De Sousa LP, Barcelos LS, Teixeira MM, Ferreira PC, Kroon EG, Souto-Padrón T, Bonjardim CA.

J Virol. 2009 Jul;83(13):6883-99. doi: 10.1128/JVI.00245-09. Epub 2009 Apr 22.

14.

c-Met is a potentially new therapeutic target for treatment of human melanoma.

Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R.

Clin Cancer Res. 2007 Apr 1;13(7):2246-53.

15.

ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase.

Yu CF, Liu ZX, Cantley LG.

J Biol Chem. 2002 May 31;277(22):19382-8. Epub 2002 Mar 14.

16.

Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.

Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J.

Curr Cancer Drug Targets. 2010 May;10(3):332-42.

PMID:
20370683
17.

Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.

Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L.

Cell Cycle. 2009 Jul 1;8(13):2050-6. Epub 2009 Jul 27.

PMID:
19502802
18.

SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.

Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, Yang X.

J Hepatol. 2004 Aug;41(2):267-73.

PMID:
15288476
19.

Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin.

Herynk MH, Tsan R, Radinsky R, Gallick GE.

Clin Exp Metastasis. 2003;20(4):291-300.

PMID:
12856716
20.

Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells.

Wong M, Uddin S, Majchrzak B, Huynh T, Proudfoot AE, Platanias LC, Fish EN.

J Biol Chem. 2001 Apr 6;276(14):11427-31. Epub 2001 Jan 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk